



Rosetta Genomics to Present at the 27th Annual ROTH Conference

PRINCETON, N.J. and REHOVOT, Israel (March 4, 2015) – Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that Company management will participate in the upcoming 27th Annual ROTH Conference being held from March 8-11, 2015 at the Ritz Carlton, Laguna Niguel in Dana Point, Calif. Ken Berlin, Rosetta's President and Chief Executive Officer, will present a corporate overview and update on March 10, 2015 at 5:30 p.m. Pacific time.

A live audio webcast of Mr. Berlin's presentation will be available in the investor section of Rosetta Genomics' website, <http://www.rosettagenomics.com>, where it will also be archived for 30 days.

About Rosetta Genomics

Rosetta develops and commercializes a full range of microRNA-based molecular diagnostics. Founded in 2000, Rosetta's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools. Rosetta's cancer testing services are commercially available through its Philadelphia-based CAP-accredited, CLIA-certified lab.

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, Rosetta's development or commercialization of molecular diagnostics or therapeutics, the market acceptance of Rosetta's cancer testing services, particularly the Rosetta Cancer Origin Test™ and the thyroid assay, Rosetta's development of personalized medicine products and services, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2013 as filed with the SEC. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

Company Contact:

Rosetta Genomics
Ken Berlin, President & CEO

(609) 419-9003
investors@rosettagenomics.com

Investor Contacts:

LHA
Anne Marie Fields
(212) 838-3777
afields@lhai.com

or

Bruce Voss
(310) 691-7100
bvoss@lhai.com

#